| Catalog No. | HF879026 |
| Brand | abinScience |
| Host species | Human |
| Tested applications | FCM |
| Species reactivity | Human |
| Form | Liquid |
| Storage buffer | 0.01M PBS pH 7.4. |
| Purity | >95% as determined by SDS-PAGE. |
| Clonality | Monoclonal |
| Isotype | IgG1, kappa |
| Applications | ELISA, Bioactivity: FCM, Functional assay, Research in vivo |
| Target | C-domain 1, C-domain 2, Cachectin, ICD1, ICD2, Intracellular domain 1, Intracellular domain 2, N-terminal fragment, NTF, TNF, TNF-a, TNF-alpha, TNFA, TNFSF2, Tumor necrosis factor, Tumor necrosis factor ligand superfamily member 2, Tumor necrosis factor, membrane form, Tumor necrosis factor, soluble form |
| References | 1. Ternant D, et al. Pharmacokinetics and concentration-effect relationship of adalimumab in rheumatoid arthritis. Br J Clin Pharmacol. 2015 Feb;79(2):286-97. [HF879026] 2. Oberoi R, et al. Targeting Tumor Necrosis Factor-α with Adalimumab: Effects on Endothelial Activation and Monocyte Adhesion. PLoS One. 2016 Jul 28;11(7):e0160145. [HF879026] |
| Purification | Protein A/G purified from cell culture supernatant. |
| Biological activity | Treatment of HUVECs with Adalimumab for up to 12 hours shows no adverse effect on their cell viability, even with a 10-fold higher concentration of Adalimumab than used in this study [2]. The elimination half-life (t 1/2) of Adalimumab is long (~20 days) [1]. The enriched fluorescent-labelled adalimumab is observed mainly in major Oil red O-positive lesions documenting good tissue penetration of the drug into the atherosclerotic plaque, without background fluorescence of the vessel wall after vehicle control injection into hypercholesterolemic Ldlr -/- mice [2]. |
| Endotoxin level | < 10 EU/mg |
| Accession | P01375 |
| Stability and Storage | Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt. |
| Alternative name | ABP501, D2E7, Adalimumab, AdalimumabBeta, 331731-18-1 |
| Note | For research use only. Not suitable for clinical or therapeutic use. |
| Isotype Control | Human IgG1 Recombinant Isotype Control Antibody (13R4) (HV080507) |
Anti-Human TNF-alpha Reference Antibody (Adalimumab, RUO)
Overview
Images
 SEC-HPLC |
SEC-HPLC detection for Research Grade Adalimumab. |
 Bioactivity |
Detects Human TNFa/TNF-alpha in indirect ELISAs. |
 Flow Cytometry |
Flow-cytometry using anti-human TNFa antibody. 293T Transtected cells were stained with an irrelevant antibody (Blue Histogram) or an anti-human TNFa monoclonal antibody (Catalog HF879026, Yellow Histogram) at a concentration of 5 µg/ml for 30 mins at RT. After washing, bound antibody was detected using a a Goat Anti-Human IgG H&L Polyclonal Antibody, FITC (abinScience: HF690414) and cells analysed on a NovoCyte Flow Cytometer. |
 SDS-PAGE |
SDS-PAGE for Research Grade Adalimumab. |